“Novartis: Radically Remaking its Drug Business”

June 11, 2009

Dr. Vasella, Chairman of Novartis, believes that focusing Novartis research on smaller, narrowly defined groups of patients will lead to more targeted and effective therapies with fewer side effects.

Read the article and watch the video

 

 

Michael Nohaile profiled in Nature Reviews Drug Discovery

April 2009

Michael Nohaile discusses his career path and new role as head of Novartis Molecular Diagnostics.

Read the article

 

 

David Epstein profiled in PharmaVOICE

April 2009

David Epstein, CEO of the Novartis Pharmaceuticals Division, discusses the growing relevance of diagnostics in drug development.

Download the article
(104 KB)